What's Going On With Anavex Life Sciences Shares Today?

Anavex Life Sciences Corp AVXL shares are trading higher Thursday after the company reported results from its Phase 2 study in patients with Parkinson's disease dementia showing beneficial effects of ANAVEX 2-73.

What To Know: Anavex said the study demonstrated longitudinal beneficial effects of ANAVEX 2-73 (blarcamesine), an oral small-molecule activator of the sigma-1 receptor, on both the primary and secondary objectives, as well as the planned primary and key secondary endpoints to be utilized in an upcoming study.

"It is encouraging that the patients' clinical symptoms consistently improved longitudinally over time during the extension phase under active ANAVEX®2-73 treatment," said Christopher Missling, president and CEO of Anavex.

"This data suggests ANAVEX®2-73's potential capability to slow and potentially reverse the life altering symptoms of Parkinson's disease."

Patient requested treatment is currently continuing beyond the study through the compassionate use Special Access Scheme.

Anavex is a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer's disease, Parkinson's disease, Rett syndrome and other central nervous system disorders.

See Also: US Stocks Eye Strong Q1 Finish As Futures Point To Higher Open: Jobless Claims, GDP Data In Focus

AVXL Price Action: Anavex shares were up 7.36% at $9.20 at time of publication, according to Benzinga Pro.

Photo: Tatiana from Pixabay.